Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01308736 · ClinicalTrials.gov registry record · NA
Varenicline-Aided Cigarette Reduction in Smokers Not Ready to Quit
A NA study of Tobacco Use Disorder, sponsored by Rutgers, The State University of New Jersey.
- Completed
- Registry status
- NA
- Development phase
- 73
- Enrollment target
- 1
- Study location
NCT01308736: Completed NA study of Tobacco Use Disorder, sponsored by Rutgers, The State University of New Jersey.
NCT01308736 is a NA study of Tobacco Use Disorder that has completed, run by Rutgers, The State University of New Jersey. The registered enrollment target is 73 participants, below the 238-participant average among 70 other Tobacco Use Disorder trials with a reported enrollment target (69% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01308736, a NA study of Tobacco Use Disorder, has completed, sponsored by Rutgers, The State University of New Jersey.
- COMPLETED
- Registry status
- NA
- Development phase
- 73 participants
- Enrollment target
- 1
- Study location
Study Summary
The investigators will randomize smokers to receive 1) Varenicline + smoking cessation/reduction counseling or 2) Placebo pill + smoking cessation/reduction counseling. Neither the participants nor the research therapists/evaluators will know to which condition (active or placebo pill) the participants have been assigned i.e., a double-blind study). The medication and weekly counseling will occur for 28 days. Participants will complete assessment measures just before the start of treatment (baseline), at the end-of-treatment, at 1-month, 3-month, and at 6-months to determine if there are differences in tobacco use between treatment groups.
Primary Outcome
50% reduction in cigarettes per day as compared to baseline. Missing data are assumed to NOT have reduced.
Conditions Studied
Interventions
- DRUG Varenicline
- DRUG Placebo pill
Study Locations (1)
New Jersey
- Division of Addiction Psychiatry - New Brunswick
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 73 participants |
| Start Date | 2011-01 |
| Est. Completion | 2014-02 |
| Phase | NA |
What the finished NCT01308736 record still lists
NCT01308736 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 73 participants, a relatively small participant target, below the 238-participant average among 70 other Tobacco Use Disorder trials with a reported enrollment target (69% lower).
The record links to 1 condition, with Tobacco Use Disorder appearing as the primary indexed condition, and to 2 interventions - of which Varenicline is the first listed.
NCT01308736 reports a single indexed study location in New Jersey.
Frequently Asked Questions
What is clinical trial NCT01308736 about?
NCT01308736 is a clinical study titled "Varenicline-Aided Cigarette Reduction in Smokers Not Ready to Quit". The investigators will randomize smokers to receive 1) Varenicline + smoking cessation/reduction counseling or 2) Placebo pill + smoking cessation/reduction counseling. Neither the participants nor the research therapists/evaluators will know to which condition (active or placebo pill) the participa...
What is the current status of trial NCT01308736?
This trial is currently completed. It is a NA study. The enrollment target is 73 participants. The study started on 2011-01. Estimated completion is 2014-02.
What conditions does trial NCT01308736 study?
This clinical trial studies the following conditions: Tobacco Use Disorder.
What interventions are being tested in trial NCT01308736?
The interventions under investigation include: Varenicline (DRUG), Placebo pill (DRUG).
Who is sponsoring clinical trial NCT01308736?
This trial is sponsored by Rutgers, The State University of New Jersey, which has 413 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01308736 being conducted?
This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Tobacco Use Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01308736's enrollment target sits among peer trials
73 45th of 70 higher than 26 of 70 other Tobacco Use Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Tobacco Use Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Smoking Cessation CM for Veterans With or at Risk for Cancer
RECRUITING · NA
-
Smoking Cessation Behavioral Treatment Study
RECRUITING · NA
-
Contingency Management for Veteran Smokers Undergoing Major Elective Surgery
RECRUITING · NA
-
A Future Thinking Intervention for Comorbid Tobacco Use Disorder and Bipolar Disorder
RECRUITING · NA
-
Young Adult Tobacco/Nicotine and Cannabis Co-use
RECRUITING · NA
-
Low Intensity Focused Ultrasound for Tobacco Use Disorder: High Resolution Targeting of the Human Insula
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03661307 · 73 participants · Phase 1
Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome
- NCT05386108 · 73 participants · Phase 1
Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer
- NCT05961592 · 73 participants · Phase 1
R-2487 in Patients With Rheumatoid Arthritis
- NCT06150664 · 73 participants · Phase 1
A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia